Astellas, Medivation submit European Marketing Authorization Application for XTANDI c

[News]

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

More... (http://www.news-medical.net/news/20140404/Astellas-Medivation-submit-European-Marketing-Authorization-Application-for-XTANDI-capsules.aspx)